Most oncology strategies are shaped by evidence and infrastructure that is built and measured in academic centers. Yet most patients are treated in community oncology settings, where biopsy timing, tissue adequacy, turnaround time for molecular results, payer utilization management and social determinants of health (SDOH) can determine whether precision medicine is delivered consistently.
In this webinar, an expert panel translates community oncology realities into clinically grounded insights for life sciences leaders developing oncology therapeutics, diagnostics and evidence strategies.
Using case-based examples and published community data, the discussion examines how community practices put “precision medicine basics” into action. This includes choosing the right test to answer certain clinical questions. For example, tumor NGS panels vs focused assays; germline testing when hereditary risk is suspected; and circulating tumor DNA (ctDNA)/liquid biopsy when tissue is limited or serial monitoring is useful. We also cover how practices coordinate ordering and interpretation across multidisciplinary teams and ensure biomarker results lead to treatment action.
Finally, the session examines why SDOH should be treated not simply as background context but as measurable factors that shape outcomes, access and the feasibility of generating longitudinal evidence in community oncology.
Featured Speakers:
Keep learning about community oncology. Subscribe now to In Practice™.
